



Clinical Resources

American Liver Foundation: [Hepatorenal Syndrome — American Liver Foundation](#)

American Liver Foundation: [Jay's Story- Hepatorenal Syndrome — American Liver Foundation](#)

Angeli P, Garcia-Tsao G, Nadim M, Parikh CR. News in pathophysiology, definition, and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. *J Hepatol*. 2019; 71(4):811-822.

Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2021; 74(2):1014-1048.

Chaney A. A review for the practicing clinician: Hepatorenal syndrome, a form of acute kidney injury, in patients with cirrhosis. *Clin and Exp Gastroenterol*. 2021; 14:385-396.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol*. 2018;69: 406-460.

Gonwa TA, Wadei HM. Kidney disease in the setting of liver failure: core curriculum 2013. *Am J Kidney Dis*. 2013 Dec; 62(6):1198-1212.

Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. *J Med Econ*. 2019; 22(5): 421-429.

Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. *Clin Gastroenterol Hepatol*. 2018; 16:162-177.

Nadim MK, Kellum JA, Davenport A, et al. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care*. 2012Feb9; 16(1):R23 <http://ccforum.com/content/16/1/R23>

Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. *Crit Care Med*. 2020;48(3): 415-419.

National Organization for Rare Disorders: [Hepatorenal Syndrome - NORD \(National Organization for Rare Disorders\) \(rarediseases.org\)](#)

Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomized clinical studies. *Aliment Pharmacol Ther*. 2017; 45: 1390-1402.

Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. *Nat Rev Nephrol*. 2020;16:137-155

Wong F, Pappas C, Curry MP, et al; for the CONFIRM study investigators. Terlipressin plus albumin for the treatment of type I hepatorenal syndrome. *N Engl J Med*. 2021; 384: 818-828.